Ian Tomlinson

University of Edinburgh
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (31)

Background: Over 20 susceptibility single-nucleotide polymorphisms (SNP) have been identified for esophageal adenocarcinoma (EAC) and its precursor, Barrett esophagus (BE), explaining a small portion of heritability. Methods: Using genetic data from 4,323 BE and 4,116 EAC patients aggregated by international consortia including the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), we conducted a comprehensive transcriptome-wide association study (TWAS) for BE/EAC, leveraging Genotype Tissue Expression (GTEx) gene-expression data from six tissue types of plausible relevance to EAC etiology: mucosa and muscularis from the esophagus, gastroesophageal (GE) junction, stomach, whole blood, and visceral adipose. Two analytical approaches were taken: standard TWAS using the predicted gene expression from local expression quantitative trait loci (eQTL), and set-based SKAT association using selected eQTLs that predict the gene expression. Results: Although the standard approach did not identify significant signals, the eQTL set–based approach identified eight novel associations, three of which were validated in independent external data (eQTL SNP sets for EXOC3 , ZNF641 , and HSP90AA1 ). Conclusions: This study identified novel genetic susceptibility loci for EAC and BE using an eQTL set–based genetic association approach. Impact: This study expanded the pool of genetic susceptibility loci for EAC and BE, suggesting the potential of the eQTL set–based genetic association approach as an alternative method for TWAS analysis.

Year:

2025

Classes of BRAF mutation exhibit distinct clinicopathologic and molecular characteristics. A, Subdivision of the large bowel into the proximal and distal colorectum. Proportions of colorectal cancers in each location are shown by BRAF mutation class. B, CMS classifications of BRAF -mutant colorectal cancers by mutation class. The differences between class 2 or 3 versus class 1 (V600E) were highly significant ( P P = 0.270). C and D, Sanger sequencing chromatograms highlighting the spatial co-occurrence of BRAF and additional Ras pathway mutations in two colorectal cancers. Two regions of each cancer were microdissected, DNA was extracted, and relevant exons were PCR-amplified prior to Sanger sequencing. Illustrative results are shown. The co-occurrence of BRAF G466V and NRAS G12D can be observed in tumor 1 ( C ), and of BRAF D594G and KRAS L19F in tumor 2 ( D ). This analysis does not exclude fine-scale spatial mixing of distinct subclones but is consistent with the two mutations tested being present in the same tumor cells. (Created with BioRender.com .)

Year:

2025

Supplementary Figure 4. Kaplan-Meier survival curves of unadjusted overall survival (OS, months) for CRCs harboring a Class 1, 2, or 3 BRAF mutation. A: Overall survival by BRAF class irrespective of additional Ras status. B: Class 1, 2, and 3 in the absence of additional Ras. C: Class 1 and 3 absent additional Ras, and class 3 with additional Ras. Survival as shown is not corrected for covariates, whereas mixed-effects models including several covariates are reported in the main text and Table 2. Class 2 samples with survival data containing additional Ras status were insufficient for this analysis, as discussed in the main text.

Year:

2025

Supplementary Figure 3. Molecular subtyping of BRAF-mutant CRCs into the consensus molecular subtypes of CRC (CMS). Left: CMS groupings within BRAF classes 1 to 3. Right: CMS groups when stratified with the A-B-C positional classifier.

Year:

2025

mRNA expression of the EGFR ligands AREG and EREG . A, Expression of AREG and EREG is significantly increased in the distal colorectum vs. proximal colon across the INTERMPHEN ( n = 119 proximal and n = 236 distal colorectum) and TCGA COADREAD ( n = 18 proximal and n = 19 distal/rectal). Log 2 FC and significance values obtained via DESeq2 analysis (see Materials and Methods). B, Expression of EREG is significantly increased in class 3 BRAF -mutant colorectal cancers vs. class 1 in the absence of a concomitant Ras mutation ( P .adj BioRender.com .)

Year:

2025

BRAF mutations in colorectal cancer comprise three functional classes: class 1 (V600E) with strong constitutive activation, class 2 with pathogenic kinase activity lower than that of class 1, and class 3 which paradoxically lacks kinase activity. Non–class 1 mutations associate with better prognosis, microsatellite stability, distal tumor location, and better anti-EGFR response. An analysis of 13 colorectal cancer cohorts ( n = 6,605 tumors) compared class 1 ( n = 709, 10.7% of colorectal cancers), class 2 ( n = 31, 0.47%), and class 3 ( n = 81, 1.22%) mutations. Class 2–mutant and class 3–mutant colorectal cancers frequently co-occurred with additional Ras pathway mutations (29.0% and 45.7%, respectively, vs. 2.40% in class 1; P KRAS noncodon 12/13/61, NRAS , or NF1 ). Ras pathway activation was highest in class 1 and lowest in class 3, with a greater distal expression of EGFR ligands (amphiregulin/epiregulin) supporting weaker BRAF driver mutations. Unlike class 1 mutants, class 3 tumors resembled chromosomally unstable colorectal cancers in mutation burdens, signatures, driver mutations, and transcriptional subtypes, whereas class 2 mutants displayed intermediate characteristics. Atypical BRAF mutations were associated with longer overall survival than class 1 mutations (HR = 0.25; P = 0.011) but lost this advantage in cancers with additional Ras mutations (HR = 0.94; P = 0.86). This study supports the suggestion that class 3 BRAF mutations amplify existing Ras signaling in a two-mutation model and that the enhancement of weak/atypical Ras mutations may suffice for tumorigenesis, with potentially clinically important heterogeneity in the class 2/3 subgroup. Implications: The heterogeneous nature of BRAF -mutant colorectal cancers, particularly among class 2/3 mutations which frequently harbor additional Ras mutations, highlights the necessity of comprehensive molecular profiling.

Year:

2025

Supplementary Table 7. Logistic regression models of CMS groups by BRAF mutation class, with covariates: tumour location (left or right colon), MSI status, age, sex, and additional Ras status (Class 1/2/3 left, A-B-C right).

Year:

2025

Supplementary Table 4. Summary data reclassified using a positional based system based on proximity to functional domains, which may hold value in exploring atypical BRAF variants not yet functionally assessed (Classes A, B, and C). A single instance of co-occurring class 2 and 3 BRAF is omitted from the total counts yet presented as MSS with no additional clinical data available.

Year:

2025

Supplementary Figure 2. Scaled Schoenfeld residuals for corresponding fixed-effect models, inclusive of study as a categorical variable, relating to mixed-effects survival models in Table 2. A. Model I compares BRAF classes across all patients irrespective of additional Ras mutation; B. Model II compares Class 1 without Ras vs Class 3 with Ras mutations; C. Model III examines additional Ras mutation status within Class 3. P-values represent significance of violation of proportional hazards assumptions.

Year:

2025

Survival analysis of BRAF -mutant colorectal cancer classes: multivariate and univariate mixed-effects Cox proportional hazards models. Model I compares BRAF classes across all patients irrespective of additional Ras mutation; model II compares class 1 without Ras vs. class 3 with Ras mutations; model III examines additional Ras mutation status within class 3. All models include study as a random effect. Both univariate and multivariate analyses were performed on identical patient cohorts per model to ensure direct comparability.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (62)

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM
View details

Rebecca C. Fitzgerald

Head of Academic Department

University of Cambridge

UNITED KINGDOM
View details

Claire Palles

Associate Professor

University of Birmingham

UNITED KINGDOM
View details

Enric Domingo

University of Oxford

UNITED KINGDOM
View details

Ines Gockel

University Hospital Leipzig

GERMANY
View details

Xiaoyu Wang

University of Florida

UNITED STATES
View details

Johannes Schumacher

Philipps-Universität Marburg

GERMANY
View details

Nicholas West

University of Leeds School of Medicine

UNITED KINGDOM
View details

Philip Quirke

Yorkshire Cancer Research Centenary Professor of Pathology

University of Leeds

UNITED KINGDOM
View details

Wong-Ho Chow

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard Houlston

Professor

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Susanna Larsson

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN
View details

Ignacio Soriano

University of Oxford

UNITED KINGDOM
View details

Axel Hillmer

Assoc. Prof

University Hospital Bonn

GERMANY
View details

Puya Gharahkhani

Team Head, Associate Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Philip Law

Institute of Cancer Research

UNITED KINGDOM
View details

Ulrike Peters

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Graeme I Murray

-

UNITED KINGDOM
View details

Thomas Schmidt

Professor of Surgical Oncology / Chief Senior Consultant

Universitätsklinikum Bonn

GERMANY
View details

Sharon B Love

Methodology Lead of Trial Conduct Research

University College London

UNITED KINGDOM
View details

Thomas Vaughan

Professor

University of Washington

UNITED STATES
View details

Ju-Sheng Zheng

Principal Investigator

Westlake University

CHINA
View details

Lesley Anderson

University of Aberdeen

UNITED KINGDOM
View details

Philip Dunne

Group Leader

Cancer Research UK Beatson Institute

UNITED KINGDOM
View details

Keisuke Kataoka

Chief

National Cancer Center Research Institute

JAPAN
View details

John de Caestecker

Honorary Professor

University of Leicester

UNITED KINGDOM
View details

Hans Prenen

Antwerp University Hospital

BELGIUM
View details

Carlo Maj

Head of Bioinformatics | Research Group Leader – Genetic Epidemiology

University of Marburg

GERMANY
View details

Prasad Iyer

Professor of Medicine and Chair

Mayo Clinic Arizona

UNITED STATES
View details

Quinn Ostrom

Assistant Professor

Duke University School of Medicine

UNITED STATES
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Viktor Koelzer

Medical Co-Director, Professor of Experimental Pathology

University of Zurich

SWITZERLAND
View details

Jesper Lagergren

Professor and Chair of Upper Gastrointestinal Cancer and Honorary Consultant Surgeon

King’s College London

UNITED KINGDOM
View details

David Whiteman

Deputy Director

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Beatrice Melin

Professor

Umea University

SWEDEN
View details

Thomas Rösch

Chief of department, Prof. Dr

-

GERMANY
View details

Stuart MacGregor

Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Yasunori Kogure

Senior Researcher

National Cancer Center Research Institute

JAPAN
View details

Dominik Heider

Diretor

University of Münster

GERMANY
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

Manuel Salto-Tellez

Lead

Institute of Cancer Research

UNITED KINGDOM
View details

Leslie Samuel

University of Aberdeen

UNITED KINGDOM
View details

Timothy Stanley Maughan

Chair

University of Oxford

UNITED KINGDOM
View details

Lijuan Wang

University of Cambridge

UNITED KINGDOM
View details

Matthias Reeh

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Simon Bach

Professor of Colorectal Surgery

University of Birmingham

UNITED KINGDOM
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Marino Venerito

-

GERMANY
View details

Paul Moayyedi

Audrey Campbell Chair of Ulcerative Colitis Research

McMaster University

CANADA
View details

Francesca M. Buffa

Full Professor, Computing Sciences, AI in Health and Life Sciences

Bocconi University

ITALY
View details

Melissa Bondy

Professor/Department Chair

Stanford University

UNITED STATES
View details

Yukinori Okada

University of Tokyo

JAPAN
View details

Janusz Jankowski

Professor

University College London

UNITED KINGDOM
View details

Joanne Edwards

Professor

University of Glasgow

UNITED KINGDOM
View details

Shuai Yuan

Karolinska Institutet

SWEDEN
View details

Geoffrey Liu

The M. Qasim Choksi Chair in Lung Cancer Translational Research

University of Toronto

CANADA
View details

Malcolm Dunlop

Professor

University of Edinburgh

UNITED KINGDOM
View details

David Sebag-Montefiore

Professor of Clinical Oncology and Health Research

University of Leeds

UNITED KINGDOM
View details

Kathryn Pennel

Research Associate

University of Glasgow

UNITED KINGDOM
View details

Yuki Saito

National Cancer Center Research Institute

JAPAN
View details

David Kerr

Professor of Cancer Medicine

University of Oxford

UNITED KINGDOM
View details